Zuranolone is an investigational drug currently being studied for postpartum depression. On August 04, 2023, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults.
The following are antidepressant subclasses and drugs
Isocarboxazid, Phenelzine, Tranylcypromine
Duloxetine, Levomilnacipran, Venlafaxine
Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Vortioxetine
Amitriptyline, Amoxapine, Clomipramine, Desipramine, Doxepin, Imipramine, Nortriptyline, Protriptyline, Trimipramine
Bupropion, Flibanserin, Mirtazapine, Nefazodone, Trazodone